Abstract:Background: Oritavancin is a new generation of semi-synthetic glycopeptide antibiotics against Gram-positive bacteria, which served as the first and only antibiotic with a single-dose therapeutic regimen to treat ABSSSI. A naturally occurring glycopeptide A82846B is the direct precursor of oritavancin. However, its application has been hampered by low yields and homologous impurities. This study established a multi-step combinatorial strategy to rationally construct a high-quality and high-efficiency biosynthesis system for A82846B and systematically optimize its fermentation process to break through the bottleneck of microbial fermentation production. Results: Firstly, based on the genome sequencing and analysis, we deleted putative competitive pathways and constructed a better A82846B-producing strain with a cleaner metabolic background, increasing A82846B production from 92 to 174 mg/L. Subsequently, the PhiC31 integrase system was introduced based on the CRISPR-Cas12a system. Then, the fermentation level of A82846B was improved to 226 mg/L by over-expressing the pathway-specific regulator StrR via the constructed PhiC31 system. Furthermore, overexpressing glycosyl-synthesis gene evaE enhanced the production to 332 mg/L due to the great conversion of the intermediate to target product. Finally, the scale-up production of A82846B reached 725 mg/L in a 15 L fermenter under fermentation optimization, which is the highest reported yield of A82846B without the generation of homologous impurities. Conclusion: Under approaches including blocking competitive pathways, inserting site-specific recombination system, overexpressing regulator, overexpressing glycosyl-synthesis gene and optimizing fermentation process, a multi-step combinatorial strategy for the high-level production of A82846B was developed, constructing a high-producing strain AO-6. The combinatorial strategies employed here can be widely applied to improve the fermentation level of other microbial secondary metabolites, providing a reference for constructing an efficient microbial cell factory for high-value natural products.

Construction of a High Epidaunorubicin-Producing Strain by Gene Recombination

Influence of Increase in the Number of aveB Ⅳ Gene Copy on Improving the Fermentation Unit of Epidaunorubicin-Producing Strain

Enhance 4′‐epidaunorubicin Production of Engineering Streptomyces Coeruleorubidus Strains Via Both Knockout of Daunorubicin‐consuming Enzymes Dnrx and Dnru, and Multiple Copies of Rate‐limiting Enzyme Avebiv

Overexpression of Avebiv Leading to the Improvement of 4′-Epidaunorubicin Production in Streptomyces Coeruleorubidus Strain SIPI-A0707

Study on cloning and expression of daunorubicin C-14 hydroxylase gene under the control of SnpR-activated snpA promoter

Influence of Inactivation of dnrU Gene on Improvement of Daunorubicin Production

Bioconversion of Deoxysugar Moieties to the Biosynthetic Intermediates of Daunorubicin in an Engineered Strain of Streptomyces Coeruleobidus

Cloning and Disruption of dnmV from Daunorubicin-producing Strain Streptomyces coeruleorubidus SIPI-1482

Enhancement of doxorubicin production in Streptomyces peucetius by genetic engineering and process optimization

Study on the separation and purification of 4'-epi-daunorubicin produced by gene engineering strain SIPI-A0707

Heterologous erythromycin production across strain and plasmid construction

Construction of High Yield Mutant of Validoxylamine A

Targeted Accumulation of Selective Anticancer Depsipeptides by Reconstructing the Precursor Supply in the Neoantimycin Biosynthetic Pathway

Biotransformation of the Antitumor Intermediate 5-Fluorouridine by Recombinantescherichia Coliwith High Pyrimidine Nucleoside Phosporylase Activity

Reassembly of the Biosynthetic Gene Cluster Enables High Epothilone Yield in Engineered Schlegelella Brevitalea.

Enhanced Cytidine Production by a Recombinant Escherichia Coli Strain Using Genetic Manipulation Strategies

Improving the level of the cytidine biosynthesis in E. coli through atmospheric room temperature plasma mutagenesis and metabolic engineering

Improvement of gougerotin and nikkomycin production by engineering their biosynthetic gene clusters

Deoxycytidine production by metabolically engineered Corynebacterium ammoniagenes

Reverse Biological Engineering Of Hrdb To Enhance The Production Of Avermectins In An Industrial Strain Of Streptomyces Avermitilis

Rational construction of a high-quality and high-efficiency biosynthetic system and fermentation optimization for A82846B based on combinatorial strategies in Amycolatopsis orientalis